HEИндивидуална стипендия2023–2024

SBS-microbe · Identification of microbial and cellular biomarkers for Short Bowel Syndrome in a combined in vitro-in vivo study

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период: 2023-01-01 → 2024-12-31
Финансиране от ЕС: 175 920 €
Участници: 2
Схема: HORIZON-TMA-MSCA-PF-EF

Линиите свързват координатора с партньорите.

Накратко на български

Микробите и клетките при синдрома на късото черво се изследват чрез модели, имитиращи човешкия стомашно-чревен тракт. Това помага да се разберат причините за лошото усвояване на хранителните вещества и увреждането на чревната бариера при пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Identification of microbial and cellular biomarkers for Short Bowel Syndrome in a combined in vitro-in vivo study

SBS-microbe is a multidisciplinary translational project aimed at expanding our knowledge on a rare but severe condition named Short Bowel Syndrome (SBS). In adults, SBS mostly occurs upon an extensive small intestinal resection, eventually resulting in intestinal failure. The alterations at both the cellular and microbial level induced by the resection contribute to severe side effects such as nutrient malabsorption and lactic acidosis, thereby compromising the patient’s quality of life. In this context, SBS-microbe aims at describing microbial, metabolic and cellular hallmarks of SBS. Specifically, the project focused on the following objectives: • Objective 1: develop an in vitro model for human gastrointestinal tract comprising representative small intestinal and colonic microbiota and applicable to mimic intestinal resections, using the state-of-the-art technology of the Simulator of Human Intestinal Microbial Ecosystem (SHIME) (WP1); • Objective 2: investigate in vitro the alterations occurring in the intestinal microbial ecology solely induced by reduced intestinal length, in an adapted SHIME model and identify key microbial altered metabolites associated to SBS (WP1); • Objective 3: validate the in vitro identified SBS-associated microbial alterations against SBS patients’ data (WP2); • Objective 4: study the impact of the altered microbiota on the integrity of the epithelial layer and barrier protection and decipher the involved cellular mechanisms, through the development of intestinal epithelial cellular models and their stimulation with samples from SHIME set-up (WP3).

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Short bowel syndrome (SBS) is a severe intestinal disorder that occurs in patients upon small bowel resection. While rare in prevalence, SBS severely affects the patient’s quality of life. SBS-microbe is a multidisciplinary translational project aimed at expanding our knowledge on SBS pathogenesis and the mechanisms for resection-induced physiological adaptations, through the identification of microbial, metabolic and cellular hallmarks. It integrates a combination of SHIME, as dynamic gastrointestinal (GI) model, with epithelial cellular models and in vivo patients’ data, to gain a better mechanistic insight in disease progression, severity and the interplay with the microbiota. It may additionally propose attractive therapeutic strategies and provide valuable tools to address physiological aspects for both healthy and pathological conditions, without the recourse to animal models. Hosted in the Center for Microbial Ecology and Technology at Ghent University, this proposal includes a secondment with SBS medical and metagenomics experts at KULeuven. The applicant’s microbiology and cell biology expertise will be expanded with reactor engineering skills, facilitating the development of novel in vitro models to address host-microbiota interactions in a simulated SBS environment. The secondment at KULeuven offers the opportunity to gain a better insight in cohort composition and identify determinants that potentially underlie the patient’s clinical condition, which is crucial for the mechanistic in vitro work. Through the development of a GI and epithelial cellular models, SBS-microbe aims at identifying key microbial and cellular signatures occurring after intestinal resection. Additionally, this will enable the proof-of-concept that targeting specific microbial and metabolic markers may significantly empower the intestinal homeostasis in SBS and ameliorate the quality of life of these patients.

Оригинален текст от CORDIS (на английски).

Участници

UNIVERSITEIT GENT · GentКоординаторБелгия
KATHOLIEKE UNIVERSITEIT LEUVEN · LeuvenБелгия